X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ALEMBIC PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ALEMBIC PHARMA DISHMAN PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 25.1 18.0 139.1% View Chart
P/BV x 3.3 4.6 73.1% View Chart
Dividend Yield % 0.7 0.7 89.5%  

Financials

 DISHMAN PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ALEMBIC PHARMA
Mar-18
DISHMAN PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs374645 58.0%   
Low Rs129470 27.4%   
Sales per share (Unadj.) Rs197.8166.1 119.1%  
Earnings per share (Unadj.) Rs21.221.9 96.8%  
Cash flow per share (Unadj.) Rs34.727.5 126.3%  
Dividends per share (Unadj.) Rs2.004.00 50.0%  
Dividend yield (eoy) %0.80.7 110.8%  
Book value per share (Unadj.) Rs179.9117.8 152.8%  
Shares outstanding (eoy) m80.69188.52 42.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.4 37.9%   
Avg P/E ratio x11.925.5 46.6%  
P/CF ratio (eoy) x7.220.3 35.7%  
Price / Book Value ratio x1.44.7 29.6%  
Dividend payout %9.418.3 51.6%   
Avg Mkt Cap Rs m20,306105,090 19.3%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3556,228 86.0%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96131,308 51.0%  
Other income Rs m26570 377.5%   
Total revenues Rs m16,22631,378 51.7%   
Gross profit Rs m4,1036,431 63.8%  
Depreciation Rs m1,0911,055 103.4%   
Interest Rs m94434 2,777.6%   
Profit before tax Rs m2,3345,413 43.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m1-81 -1.4%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,204 51.8%   
Profit after tax Rs m1,7114,128 41.4%  
Gross profit margin %25.720.5 125.2%  
Effective tax rate %26.722.2 120.2%   
Net profit margin %10.713.2 81.3%  
BALANCE SHEET DATA
Current assets Rs m11,01818,247 60.4%   
Current liabilities Rs m9,51711,235 84.7%   
Net working cap to sales %9.422.4 42.0%  
Current ratio x1.21.6 71.3%  
Inventory Days Days11086 129.1%  
Debtors Days Days3561 56.8%  
Net fixed assets Rs m16,30420,035 81.4%   
Share capital Rs m161377 42.8%   
"Free" reserves Rs m12,90721,824 59.1%   
Net worth Rs m14,51622,201 65.4%   
Long term debt Rs m4,1895,000 83.8%   
Total assets Rs m29,80539,411 75.6%  
Interest coverage x3.5160.2 2.2%   
Debt to equity ratio x0.30.2 128.2%  
Sales to assets ratio x0.50.8 67.4%   
Return on assets %8.910.6 84.4%  
Return on equity %11.818.6 63.4%  
Return on capital %17.519.7 88.9%  
Exports to sales %24.846.4 53.4%   
Imports to sales %3.710.5 35.6%   
Exports (fob) Rs m3,95614,535 27.2%   
Imports (cif) Rs m5963,288 18.1%   
Fx inflow Rs m4,95214,722 33.6%   
Fx outflow Rs m6977,026 9.9%   
Net fx Rs m4,2557,696 55.3%   
CASH FLOW
From Operations Rs m2,7863,124 89.2%  
From Investments Rs m-1,529-8,844 17.3%  
From Financial Activity Rs m-9415,026 -18.7%  
Net Cashflow Rs m316-693 -45.6%  

Share Holding

Indian Promoters % 61.4 74.1 82.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 2.9 127.6%  
FIIs % 12.7 9.1 139.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 13.9 159.0%  
Shareholders   46,261 49,328 93.8%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  DIVIS LABORATORIES  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Where Will the Two-Faced Market Go from Here?(Podcast)

The stock markets are very volatile these days. As the Tanushree Bannerjee, the co-head of research here at Equitymaster puts it, stock markets are two-faced.

Related Views on News

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

Feb 4, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

Here's What the Biggest 'Rebirth of India' Investors are Doing(The 5 Minute Wrapup)

Feb 5, 2019

A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Do You Have the Stomach to Survive a Small Cap Crash?(Profit Hunter)

Feb 5, 2019

While selecting good businesses is relatively easy task in a bearish phase, where most people fail is in having enough patience to hold the quality stocks until recovery.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - TORRENT PHARMA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS